Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Vicki L. Seyfert-Margolis"'
Autor:
Newell E. McElwee, Peter K. Honig, Norman Stockbridge, Harry P. Selker, Hans-Georg Eichler, Kenneth I. Kaitin, Theodora Cohen, John K. Erban, Vicki L. Seyfert-Margolis, Willard H. Dere, Kenneth A. Oye, Ralph B. D'Agostino
Publikováno v:
Clinical Pharmacology and Therapeutics
Efficacy trials, designed to gain regulatory marketing approval, evaluate drugs in optimally selected patients under advantageous conditions for relatively short time periods. Effectiveness trials, designed to evaluate use in usual practice, assess t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e88cd3eb51ccd5afd622e80251782b
http://europepmc.org/articles/PMC6422692
http://europepmc.org/articles/PMC6422692
Autor:
Kenneth A. Oye, Kenneth I. Kaitin, Newell E. McElwee, Heather C. Kaplan, Ralph B. D'Agostino, Richard L. Kravitz, Kay Larholt, Hans Georg Eichler, Willard H. Dere, Chandra Ramanathan, S. Nassir Ghaemi, Mark R. Trusheim, Eleanor M. Perfetto, Vicki L. Seyfert-Margolis, Marisha E. Palm, Theodora Cohen, Christopher H. Schmid, Peter Honig, Harry P. Selker
Publikováno v:
Clinical pharmacology and therapeutics. 112(2)
Clinicians and patients often try a treatment for an initial period to inform longer-term therapeutic decisions. A more rigorous approach involves N-of-1 trials. In these single-patient crossover trials, typically conducted in patients with chronic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1354af192cccc8bd0743b15002a21ff5
https://pubmed.ncbi.nlm.nih.gov/34551122
https://pubmed.ncbi.nlm.nih.gov/34551122
Autor:
Nathan Buijsse, Joost F. Swart, Nico M Wulffraat, Mark Klein, Sytze de Roock, Vicki L. Seyfert-Margolis, Martijn J. H. Doeleman, Gouke J. Bonsel
Publikováno v:
Pediatric Rheumatology, 19, 1. BMC
Pediatric Rheumatology Online Journal, Vol 19, Iss 1, Pp 1-7 (2021)
Pediatric Rheumatology Online Journal
Pediatric Rheumatology, 19(1):40. BioMed Central Ltd.
Pediatric Rheumatology Online Journal, Vol 19, Iss 1, Pp 1-7 (2021)
Pediatric Rheumatology Online Journal
Pediatric Rheumatology, 19(1):40. BioMed Central Ltd.
Background Pediatric patients with juvenile idiopathic arthritis (JIA) are at risk for a lower health-related quality of life compared to their healthy peers. Remote monitoring of health-related quality of life using electronic patient-reported outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89fb1453ae84b6e4d21143d86ab394b
http://www.scopus.com/inward/record.url?scp=85103162695&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85103162695&partnerID=8YFLogxK
Autor:
Lynn G. Baird, E. V. Sigal, Jeffrey S. Brown, D. Tan, Robyn Lim, H. G. Eichler, Kenneth A. Oye, Vicki L. Seyfert-Margolis, E Pezalla, J Ferguson, Brian O'Rourke, Sarah Garner, J. Sobotka, John C W Lim, Chester L. Drum, Thomas F. Unger, P. Honig, Diane Shoda, Mathias Hukkelhoven, G. Neil, E. Abadie, M. M. Lumpkin, Gigi Hirsch
Publikováno v:
Clinical Pharmacology & Therapeutics. 91:426-437
Traditional drug licensing approaches are based on binary decisions. At the moment of licensing, an experimental therapy is presumptively transformed into a fully vetted, safe, efficacious therapy. By contrast, adaptive licensing (AL) approaches are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::245a5f02aea1ed485744329305690ab5
https://doi.org/10.1038/clpt.2011.345
https://doi.org/10.1038/clpt.2011.345